Toxic Injury to the Gastrointestinal Tract After Ipilimumab Therapy for Advanced Melanoma.

Toxic Injury to the Gastrointestinal Tract After Ipilimumab Therapy for Advanced Melanoma. J Am Osteopath Assoc. 2018 Jan 01;118(1):40-44 Authors: Shepard B, Trower C, Hendrickson S Abstract Ipilimumab, cytotoxic T-lymphocyte-associated protein 4-blocking antibody, is known to precipitate tissue-specific immune-related adverse events. The second most common site for immune-related adverse events is the gastrointestinal tract, with toxic injury resulting in diarrhea, colitis, and enterocolitis. In the present case, a woman who received ipilimumab 2 weeks prior was found to have severe, diffuse corticosteroid-refractory gastrointestinal tract toxic injury affecting the stomach, small bowel, and colon. PMID: 29309091 [PubMed - in process]
Source: Journal of the American Osteopathic Association - Category: Complementary Medicine Tags: J Am Osteopath Assoc Source Type: research